Boehringer Ingelheim develops cutting-edge viral therapeutics therapies with a focus on gene therapies, cancer vaccines and oncolytic viruses by combining its world class, in-house research and development with that of highly innovative external companies. In your new role as a scientist for drug substance development you can be part of building our new and innovative pharmaceutical development platform of viral therapeutics. Drug substance development starts in parallel with preclinical development and ends with a successful marketing authorization application ( M...